Table 5. Joint effects on prostate cancer risk of gene promoter methylation status at RARB and APC.
| Combined Gene Methylation Status | % Methylated | Crude Model | Adjusted Model* | |||
|---|---|---|---|---|---|---|
|
|
|
|
||||
| Controls | Cases | OR (95% CI) | p Value | OR (95% CI) | p Value | |
| Overall: | ||||||
| APC−/RARB− | 63.1 | 54.2 | 1 | 1 | ||
| APC+/RARB− | 14.6 | 12.4 | 0.99 (0.65–1.53) | >0.9 | 0.96 (0.61–1.49) | 0.8 |
| APC−/RARB+ | 14.1 | 20.0 | 1.69 (1.14–2.51) | 0.009 | 1.45 (0.96–2.18) | 0.08 |
| APC+/RARB+ | 8.2 | 13.4 | 1.91 (1.19–3.08) | 0.008 | 1.85 (1.12–3.05) | 0.02 |
| Black: | ||||||
| APC−/RARB− | 59.3 | 42.6 | 1 | 1 | ||
| APC+/RARB− | 16.0 | 11.7 | 1.06 (0.51–2.22) | 0.9 | 1.00 (0.47–2.12) | >0.9 |
| APC−/RARB+ | 15.4 | 25.9 | 2.19 (1.22–3.93) | 0.009 | 1.88 (1.02–3.46) | 0.04 |
| APC+/RARB+ | 9.3 | 19.8 | 2.96 (1.44–6.05) | 0.003 | 3.04 (1.44–6.42) | 0.004 |
| White: | ||||||
| APC−/RARB− | 65.7 | 62.0 | 1 | 1 | ||
| APC+/RARB− | 13.6 | 12.8 | 0.99 (0.58–1.68) | >0.9 | 0.96 (0.55–1.69) | 0.9 |
| APC−/RARB+ | 13.2 | 16.1 | 1.34 (0.77–2.33) | 0.3 | 1.19 (0.67–2.11) | 0.6 |
| APC+/RARB+ | 7.4 | 9.1 | 1.29 (0.67–2.49) | 0.4 | 1.14 (0.56–2.30) | 0.7 |
*
Adjusted for PSA and HGPIN